
You are currently analyzing a numeric forecasting question to generate a final, inside view prediction.

The forecasting question is:
What will be the reported Q1 2026 global revenue for Zepbound (tirzepatide)?

This question's outcome will be determined by the specific criteria below. These criteria have not yet been satisfied:
This question resolves to the value of the 'Global' or 'Total' net sales (revenue) for Zepbound (tirzepatide) for the first quarter (Q1) of 2026, as reported in Eli Lilly and Company's quarterly earnings materials. Resolution will be based on the first official earnings release or SEC filing (10-Q) issued by Eli Lilly and Company for the quarter ending March 31, 2026. Source: https://investor.lilly.com/financial-information/quarterly-results

Additional fine-print:


Units for answer: $

Question metadata:
- Opened for forecasting: 2026-02-01T19:30:00Z
- Resolves: 2026-05-01T00:00:00Z

IMPORTANT: Today's date is 2026-02-01. All dates before today's date are in the PAST. All dates after today's date are in the FUTURE. Use today's date to correctly evaluate whether sources describe past events or future predictions. Any information source which refers to events before today's date of 2026-02-01 should not be considered as speculative but rather an historical document.

The lower bound is 0.0 and the upper bound is 10000000000.0.
The lower bound is CLOSED (outcome cannot be below 0.0), but the upper bound is OPEN (outcome can exceed 10000000000.0). Your upper percentiles may extend beyond the upper bound if evidence supports it.

Outside view analysis + current information/news articles:

<Summary source="https://www.statnews.com/2025/10/30/eli-lilly-zepbound-mounjaro-bestselling-obesity-drug/">
# Summary of Article: "Eli Lilly's weight loss and diabetes drug tops Keytruda as world's best-selling medicine"

**Source:** STAT  
**Date:** October 30, 2025  
**Author:** Elaine Chen

## Key Facts and Statistics:

1. **Tirzepatide (Mounjaro/Zepbound) Sales Performance:**
   - Q3 2025 sales: $10.1 billion
   - Year-to-date sales (through Q3 2025): $24.8 billion
   - Full-year 2025 analyst prediction (Visible Alpha): $32.2 billion

2. **Keytruda (Merck) Sales for Comparison:**
   - Q3 2025 sales: $8.1 billion
   - Year-to-date sales (through Q3 2025): $23.3 billion
   - Full-year 2025 analyst prediction (Visible Alpha): $31.8 billion

3. **Eli Lilly Total Company Performance (Q3 2025):**
   - Total revenue: $17.6 billion (exceeded analyst predictions of $16.1 billion)
   - Updated full-year 2025 sales guidance: $63-63.5 billion (raised from previous $60-62 billion)
   - Updated adjusted earnings per share guidance: $23.00-23.70 (raised from previous $21.75-23.00)

4. **Approval Timeline:**
   - Tirzepatide approved for diabetes: 2022
   - Tirzepatide approved for obesity: 2024
   - Keytruda became best-selling drug nine years after approval

## Key Context:

- Tirzepatide has now surpassed Keytruda as the world's best-selling medicine on a year-to-date basis
- This is the second consecutive quarter where tirzepatide sales exceeded Keytruda on a quarterly basis
- Lilly is viewed as having surpassed Novo Nordisk (maker of Ozempic and Wegovy) with a drug that can lead to even greater weight loss
</Summary>

<Summary source="https://www.biopharmadive.com/news/lilly-third-quarter-2025-earnings-zepbound-mounjaro-obesity-sales/804232/">
# Article Summary: Lilly hikes revenue forecasts on booming obesity drug sales

**Source:** BioPharma Dive  
**Date:** October 30, 2025  
**Author:** Kristin Jensen

## Key Facts and Statistics:

1. **Q3 2025 Performance:**
   - Tirzepatide (Zepbound for obesity + Mounjaro for diabetes) combined revenue: $10.1 billion in Q3 2025
   - This represents an increase from $4.37 billion in Q3 2024
   - Tirzepatide became the world's best-selling drug in Q3 2025, surpassing Merck's Keytruda ($8.1 billion)

2. **Overall Q3 2025 Results:**
   - Lilly's total Q3 revenue beat analyst expectations by 9%
   - Earnings per share were 19% higher than consensus (according to Leerink Partners)

3. **Updated Full-Year 2025 Forecasts:**
   - Revenue: $63 billion to $63.5 billion (raised from previous $60-62 billion estimate)
   - Earnings per share: $21.80 to $22.50 (raised from previous $20.85 to $22.10 estimate)

## Market Context and Strategic Information:

- Analysts expect the GLP-1 market to exceed $100 billion in the next decade
- Lilly's stock price has remained relatively flat over the past 12 months despite strong Zepbound/Mounjaro sales
- The company has faced challenges including sales occasionally falling short of high analyst expectations and revenue loss to compounders during manufacturing shortfalls
- Lilly has shown Zepbound beat Novo's Wegovy in a head-to-head weight loss study
- The company recently announced a deal with Walmart (mid-November implementation) to provide discounted drugs to customers
- Lilly is investing heavily in production capacity for an experimental obesity pill before approval
</Summary>

<Summary source="https://www.prnewswire.com/news-releases/lilly-reports-third-quarter-2025-financial-results-highlights-rd-pipeline-momentum-and-raises-2025-guidance-302599148.html">
# Summary of Eli Lilly Q3 2025 Financial Results

## Key Financial Metrics (Q3 2025):
- **Worldwide revenue**: $17.60 billion (54% increase year-over-year)
- **Revenue growth drivers**: 62% increase in volume, partially offset by 10% decrease due to lower realized prices
- **U.S. revenue**: $11.30 billion (45% increase)
- **Revenue outside U.S.**: $6.30 billion (74% increase)

## Zepbound-Specific Results (Q3 2025):
- **U.S. Zepbound revenue**: $3.57 billion (184% increase compared to Q3 2024's $1.26 billion)
- **Primary driver**: Increased demand, partially offset by lower realized prices
- **Note**: The article only reports U.S. revenue for Zepbound; no global/total revenue figure is provided for this product

## Other Key Product Results (Q3 2025):
- **Mounjaro worldwide revenue**: $6.52 billion (109% increase)
  - U.S.: $3.55 billion (49% increase)
  - Outside U.S.: $2.97 billion (compared to $728.0 million in Q3 2024)
- **Key Products revenue** (defined as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio, and Zepbound): $11.98 billion

## Manufacturing and Pipeline Updates:
- CEO David A. Ricks stated: "We continue to increase manufacturing capacity, announcing new facilities in Virginia and Texas and an expansion of our site in Puerto Rico."
- Orforglipron advanced through four additional Phase 3 trials, enabling global obesity submissions by year-end

## Context for Forecasting:
This is Q3 2025 data. The question asks about Q1 2026 revenue, which would be reported approximately 6 months after this report. The article shows strong growth trajectory for Zepbound (184% YoY) but only provides U.S. revenue figures, not global totals.
</Summary>

<Summary source="https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html">
# Summary of Article: Eli Lilly Q4 2024 Earnings Report

**Date:** February 6, 2025  
**Source:** CNBC  
**Author:** Annika Kim Constantino

## Key Facts and Statistics:

### Overall Q4 2024 Performance:
- **Total Revenue:** $13.53 billion (up 45% year-over-year)
- **Net Income:** $4.41 billion ($4.88 per share)
- **Adjusted Earnings:** $5.32 per share (excluding one-time items)
- **Result:** Earnings beat Wall Street estimates; sales fell slightly short

### Zepbound (Tirzepatide) Performance:
- **Q4 2024 Revenue:** $1.91 billion
- **Analyst Expectations:** $1.98 billion (underperformed by ~$70 million)
- **Notable Achievement:** Became market leader in obesity market in Q4 as measured by new prescriptions
- **Context:** This was Zepbound's first full year on the U.S. market
- **Pattern:** Underperformed expectations for two straight quarters

### Mounjaro (Tirzepatide) Performance:
- **Q4 2024 Revenue:** $3.53 billion (up 60% year-over-year)
- **Analyst Expectations:** $3.62 billion (underperformed by ~$90 million)
- **Revenue Impact:** Lower realized prices due to "favorable changes" in Q4 2023 estimates for rebates and discounts

### 2025 Guidance:
- **Fiscal 2025 Profit Guidance:** $22.05 to $23.55 per share (in line with analyst expectations)
- **Fiscal 2025 Sales Guidance:** $58 billion to $61 billion (reiterated)
- **Production Forecast:** At least 1.6 times the amount of incretin doses in first half of 2025 compared to first half of 2024

## Opinions from Named Sources:

**CFO Lucas Montarce (during earnings call):**
- Expects "a continuation of basically the total prescription growth that we have seen in 2024" for incretin drugs such as Zepbound and Mounjaro
- This expectation is built into the 2025 guidance

## Additional Context:
- Demand in the U.S. has far outpaced supply for incretin drugs over the last year
- FDA declared the U.S. shortage of tirzepatide over in December 2024
- Company previously pointed to inventory decreases among wholesalers as a factor in underperformance
- Eli Lilly plans to launch Mounjaro in new international markets throughout 2025
- Company shares rose more than 4% on the day of the earnings report
</Summary>

<Summary source="https://www.biospectrumasia.com/company-results/102/25588/eli-lilly-reports-record-q4-2024-revenue-of-13-53b-fueled-by-mounjaro-zepbound-and-oncology-growth.html">
# Summary of Article: Eli Lilly Q4 2024 Financial Results

## Key Facts and Statistics Relevant to Zepbound:

**Q4 2024 Zepbound Revenue:**
- Zepbound generated **$1.2 billion in sales** during Q4 2024
- The article describes this as following its U.S. FDA approval and launch, with "rapid uptake" highlighting growing demand for weight management solutions

## Other Relevant Context:

**Overall Company Performance (Q4 2024):**
- Total revenue: $13.53 billion (45% increase)
- Gross margin: 83.2%
- R&D spending increased by 18%

**Mounjaro Performance:**
- Generated $3.5 billion in Q4 2024 sales (Mounjaro uses the same active ingredient as Zepbound - tirzepatide - but for Type 2 diabetes)

**Zepbound Pipeline/Regulatory Developments:**
- Received U.S. FDA approval as first prescription medication for moderate-to-severe obstructive sleep apnea in adults with obesity
- Phase 3b SURMOUNT-5 study showed Zepbound delivered 47% greater weight loss compared to Wegovy
- SUMMIT Phase 3 study of tirzepatide showed promising results in reducing risk of heart failure

**Manufacturing and Strategic Developments:**
- $3 billion manufacturing expansion in Wisconsin to enhance global production capabilities and meet growing demand
- This expansion is expected to support production of key products across multiple therapeutic areas

---

**Note:** This article reports Q4 2024 results and does not contain information about Q1 2026 revenue projections or forecasts for Zepbound.
</Summary>

<Summary source="https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/37197042/heres-how-eli-lillys-oncology-drugs-are-poised-ahead-of-q4-earnings/">
# Summary of Article: "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings"

**Date:** January 23, 2026  
**Source:** The Globe and Mail

## Key Facts and Statistics:

1. **Oncology Revenue Performance (First 9 Months of 2025):**
   - Eli Lilly's oncology sales totaled $6.77 billion
   - Year-over-year growth of approximately 9%
   - Oncology accounted for around 15% of company's total revenue

2. **Q4 2025 Expectations:**
   - Zacks Consensus Estimate for oncology portfolio sales in Q4 2025: $2.64 billion
   - Eli Lilly scheduled to report Q4 2025 earnings on February 4, 2026

3. **Stock Performance:**
   - Eli Lilly shares gained 35% in the past six months (compared to industry's 19.1% growth)
   - Current forward P/E ratio: 32.02 (vs. industry average of 18.08)
   - Trading below its five-year mean P/E of 34.56

4. **Earnings Estimates:**
   - 2025 earnings estimates: declined from $23.95 to $23.83 per share in past 60 days
   - 2026 earnings estimates: improved from $33.36 to $33.41 per share over same timeframe

## Key Product Information:

- **Verzenio** (breast cancer drug): Expected to generate significant portion of oncology revenue
- **Inluriyo** (imlunestrant): New breast cancer drug approved by FDA in late September 2025, launched in Q4 2025 in the U.S. - investors awaiting initial sales numbers
- Other contributing drugs: Retevmo (RET inhibitor), Jaypirca (lymphoma drug)
- Declining drugs: Alimta and Cyramza (facing competition from immuno-oncology agents)

## Context on Zepbound/Tirzepatide:

The article notes that Eli Lilly is a market leader in the GLP-1 segment with tirzepatide medicines Mounjaro (diabetes) and Zepbound (obesity), though no specific revenue figures for Zepbound are provided in this article.

**Note:** This article focuses primarily on Eli Lilly's oncology business and does not contain specific Q1 2026 revenue data or forecasts for Zepbound.
</Summary>

<Agent_report>
Query: Compile tirzepatide (Mounjaro & Zepbound) quarterly revenues 2023-2025 and capacity expansion timelines; summarize in table
Below is an updated, source-backed consolidation of (A) tirzepatide revenues by quarter and (B) Eli Lilly’s disclosed manufacturing-capacity build-out through January 2026, followed by the open items that still require verification.

A. Mounjaro & Zepbound – quarterly revenue scorecard  
(values in USD billions; “—” = product not yet launched)

Quarter  | Mounjaro | Zepbound | Key source(s)
-----------|----------|----------|---------------
Q1-23 | 0.567 | — | CNBC/BioSpace earnings wrap 30 Apr 2024
Q2-23 | 0.980 | — | Yahoo Finance (Zacks) 08 Aug 2023
Q3-23 | 1.410 | — | CNBC 02 Nov 2023
Q4-23 | ≥2.200 | 0.175 | BioSpace 06 Feb 2024
FY-23 | ≥5.167 | 0.175 | subtotal of quarters above
Q1-24 | 1.810 | 0.517 | CNBC & BioSpace 30 Apr 2024
Q2-24 | 3.090 | 1.240 | CNBC 08 Aug 2024
Q3-24 | 3.112 | 1.257 | AOL/Motley-Fool call transcript 22 Jan 2026; DrugDiscoveryTrends 03 Nov 2025
Q4-24 (derived) | ≈3.50 | ≈1.94 | FY totals minus Q1-Q3; FY-24 split confirmed by Fierce Pharma 26 Feb 2025
FY-24 | 11.5 | 4.9 | Fierce Pharma 26 Feb 2025
Q1-25 | n/a | n/a | no public figure located
Q2-25 | 5.200 | 3.380 | Eli Lilly press release 07 Aug 2025
Q3-25 | 6.515 | 3.588 | DrugDiscovery & Development 03 Nov 2025; BioSpace 30 Oct 2025
Q4-25 | n/a | n/a | results expected Feb-26

Observations  
• 2023 is now fully populated for Mounjaro; quarterly data for Zepbound start Q4-23.  
• 2024 is almost complete—only Q4 figures are inferred from Lilly’s stated FY totals.  
• 2025 now has product-level splits for Q2 and Q3, eliminating the earlier “combined” gap for Q2.  
• Definitive numbers are still absent for Q1-25 and Q4-25; Lilly has not yet published them.

B. Manufacturing & capacity-expansion timeline (tirzepatide and broader incretin portfolio)

Site / location | Investment & announcement date | Scope (API / fill-finish / device) | Target operational date | Relevance | Source
--------------- | ----------------------------- | ---------------------------------- | ----------------------- | --------- | ------
Lebanon, Indiana (LP-1/LP-2 + “Medicine Foundry”) | +$5.3 bn May 2024 (on top of prior $3.7 bn) | Bulk API, autoinjector assembly, large-scale injectables | First modules Dec-2027 | Flagship U.S. hub for tirzepatide & next-gen incretins | Fierce Pharma 26 Feb 2025
Pleasant Prairie/Kenosha Co., Wisconsin | $3 bn Dec 2024 (site total >$4 bn) | High-volume fill-finish & secondary packaging | 1H-2026 first lots | Near-term U.S. supply relief | BioProcess Int’l & CNBC 05 Dec 2024
Concord, North Carolina | $1.7 bn (plan reiterated Feb 2025) | Parenteral products & devices | 2027 | Additional GLP-1 capacity | Fierce Pharma 26 Feb 2025
Research Triangle Park, NC | $450 m add-on Jul 2025 | Vial/pen filling, device assembly | 2027 | Supplements Concord output | BioBuzz 16 Jul 2025
Alzey, Germany | $2.5 bn (ground-breaking 2024) | European GLP-1 bulk drug | 2027 | First EU tirzepatide API site | Fierce Pharma 26 Feb 2025
Irish network (Limerick & others) | $1.8 bn Sept 2024 | API + drug product | Est. 2027-28 | Diversifies EU supply | BioSpace 06 Dec 2024
Four new U.S. “mega-sites” (locations TBA) | $27 bn pledge Feb 2025 | 3 API plants, 1 injectables | By ~2030 | Long-range global supply | Fierce Pharma 26 Feb 2025
Fogelsville, Pennsylvania | $3.5 bn Jan 2026 | Large-volume incretin injectables | 2031 | Fourth-wave U.S. capacity | CNBC & PA-DCED 30 Jan 2026
Katwijk, Netherlands (Leiden Bio Sci Park) | $3 bn Nov 2025 | Oral GLP-1 (orforglipron) manufacturing | Construction starts 2026 | Frees injectable capacity for tirzepatide | DrugDiscovery & Development 03 Nov 2025
Puerto Rico site (expansion) | undisclosed 2025 | Small-molecule GLP-1 & advanced therapies | Not stated | U.S. on-shoring push | DrugDiscovery & Development 03 Nov 2025
Texas & Virginia greenfields | planning 2025 | APIs / biologics | Not stated | Part of $27 bn “mega-site” set | DrugDiscovery & Development 03 Nov 2025
Nexus Pharma facility, WI (acquired) | price undisclosed Q1-24 | Sterile injectables | Integrated 2024 | Short-term capacity bump | CNBC 30 Apr 2024

Key takeaways  
• Lilly’s committed manufacturing outlays for incretin medicines now exceed $50 billion since 2020.  
• The first meaningful incremental supply for tirzepatide is expected late-2025 (Pleasant Prairie) and 2027 (Lebanon, Concord, RTP, Alzey, Ireland).  
• A second wave of mega-plants (Texas, Virginia + two TBD U.S. sites) targets 2030 readiness, aligning with forecasted demand for both injectable and oral GLP-1s.

C. Remaining information gaps

Revenue data still missing  
1. Q1-25 and Q4-25 product-level sales for Mounjaro and Zepbound.  
2. Precise Q4-23 Mounjaro figure (company only said “> $2.2 bn”).  
3. Validation of the derived Q4-24 numbers once Lilly files its 2024 Form 10-K.

Manufacturing detail still missing  
1. Month-specific commissioning milestones for Concord-NC, Alzey-DE and Irish facilities.  
2. Exact locations and build schedules for the four $27 bn “mega-sites” (only Texas and Virginia publicly identified so far; two remain undisclosed).  
3. Any contract-manufacturing (CMO) agreements that may supplement Lilly’s own network between now and 2027.

D. Suggested next steps  
• Retrieve Lilly’s Form 10-Q filings for Q1-25 and Q4-25 (to be issued Feb 2026) to close the revenue series. Targeted keyword: “tirzepatide revenue Q1 2025 10-Q”.  
• Monitor local planning-board minutes in Texas and Virginia plus federal permitting databases for site-specific timelines on the announced mega-plants.  
• Screen specialist CMO news outlets (e.g., PharmaTech, BioProcess Insider) for any fill-finish contracts referencing tirzepatide.

With the new data points captured above, the tirzepatide quarterly revenue record is now complete through Q3 2025 and Lilly’s capacity-expansion roadmap is current through the January 2026 Pennsylvania and Netherlands announcements. Remaining holes are clearly identified for future follow-up.</Agent_report>


The information has been sourced from the internet/language models (for agent reports), so it is advisable to exercise healthy skepticism at your discretion.


Your analysis should have the following components, refering the above historical context:
(a) Source analysis: Briefly summarize each information source (either web article or Agent report), evaluate source quality and date.
**Opinions are commonplace in writing. For each source, you must be able to discern factual information from opinions. You are advised to strongly consider only opinions originating from identifiable experts or entities**.
(b) Reference class analysis: Identify a few possible reference classes and evaluate respective suitabilities to the forecasting question. If applicable, choose the most suitable one.
(c) Timeframe analysis: State the prediction timeframe (e.g., how many days/months from now?) and examine historical patterns over similar periods
(d) Justification: Integrate the above factors with other points you found relevant to write a justification for your outside view prediction.

You are free to include other components to deepen the analysis, at your discretion.

Subsequently, calibrate your outside view prediction, considering:
(a) You aim to predict a true probability distribution, not a hedged smooth distribution or an overconfident extremely narrow distribution. In your thinking, always consider ranges over singular values.
(b) Are there previously established distributions that you can tether your prediction to?
(c) Small changes in percentile location values can disproportionately reshape the slope and overall distribution of the extrapolated CDF, esepcially near the tails.
(d) Historically, what is the rate of upsets/unexpected outcomes in the domain of this forecasting question? How should this affect your CDF distribution?

It might be a good idea to set a wide 90/10 confidence intervals to account for unknown unknowns.

For your final outside view prediction, please keep in mind the following:
- Please notice the units requested (e.g. whether you represent a number as 1,000,000 or 1m).
- Never use scientific notation.

**CRITICAL: Percentile values MUST be strictly increasing.**
- Percentile 10 = low value (only 10% of outcomes fall below this)
- Percentile 90 = high value (90% of outcomes fall below this)
- Each percentile value must be GREATER than the previous one

Format your answer as below:

Analysis:
{Insert your analysis here, following the above components.}

Outside view calibration:
{Insert your calibration of your outside view prediction here.}

Outside View Prediction:
Percentile 10: XX
Percentile 20: XX
Percentile 40: XX
Percentile 60: XX
Percentile 80: XX
Percentile 90: XX
